Presentation is loading. Please wait.

Presentation is loading. Please wait.

Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the.

Published byMiina Siitonen Modified over 6 years ago

Similar presentations

Presentation on theme: "Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the."— Presentation transcript:

1 Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study by Samantha C. Gouw, Johanna G. van der Bom, Günter Auerswald, Carmen Escuriola Ettinghausen, Ulf Tedgård, and H. Marijke van den Berg Blood Volume 109(11): June 1, 2007 ©2007 by American Society of Hematology

2 Cumulative incidence of clinically relevant inhibitor development according to switching products.
Samantha C. Gouw et al. Blood 2007;109: ©2007 by American Society of Hematology

Download ppt "Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the."

Similar presentations

A lower risk of recurrent venous thrombosis in women compared with men is explained by sex-specific risk factors at time of first venous thrombosis in.

A lower risk of recurrent venous thrombosis in women compared with men is explained by sex-specific risk factors at time of first venous thrombosis in.
Detection of antibody-mediated reduction of annexin A5 anticoagulant activity in plasmas of patients with the antiphospholipid syndrome by Jacob H. Rand,

Detection of antibody-mediated reduction of annexin A5 anticoagulant activity in plasmas of patients with the antiphospholipid syndrome by Jacob H. Rand,
Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry by Gunnar Juliusson, Petar Antunovic,

Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry by Gunnar Juliusson, Petar Antunovic,
Dosing lepirudin in patients with heparin-induced thrombocytopenia and normal or impaired renal function: a single-center experience with 68 patients by.

Dosing lepirudin in patients with heparin-induced thrombocytopenia and normal or impaired renal function: a single-center experience with 68 patients by.
Predictors of venous thromboembolism recurrence and bleeding among active cancer patients: a population-based cohort study by Cheng E. Chee, Aneel A. Ashrani,

Predictors of venous thromboembolism recurrence and bleeding among active cancer patients: a population-based cohort study by Cheng E. Chee, Aneel A. Ashrani,
How I treat HHV8/KSHV-related diseases in posttransplant patients by Giovanni Riva, Mario Luppi, Patrizia Barozzi, Fabio Forghieri, and Leonardo Potenza.

How I treat HHV8/KSHV-related diseases in posttransplant patients by Giovanni Riva, Mario Luppi, Patrizia Barozzi, Fabio Forghieri, and Leonardo Potenza.
Generating AML-Specific Peripheral Blood Autologous Cytotoxic T-Lymphocytes (CTLs)‏ by Rohtesh S. Mehta, Xiaohua Chen, Antony Jeyaraj, and Paul Szabolcs.

Generating AML-Specific Peripheral Blood Autologous Cytotoxic T-Lymphocytes (CTLs)‏ by Rohtesh S. Mehta, Xiaohua Chen, Antony Jeyaraj, and Paul Szabolcs.
The clinical significance of tumor necrosis factor-α plasma level in patients having chronic lymphocytic leukemia by Alessandra Ferrajoli, Michael J. Keating,

The clinical significance of tumor necrosis factor-α plasma level in patients having chronic lymphocytic leukemia by Alessandra Ferrajoli, Michael J. Keating,
by Paul A. Carpenter, Meei-Li Huang, and George B. McDonald

by Paul A. Carpenter, Meei-Li Huang, and George B. McDonald
The case for wider use of recombinant factor VIII concentrates

The case for wider use of recombinant factor VIII concentrates
DAR, a New RhD Variant Involving Exons 4, 5, and 7, Often in Linkage With ceAR, a New Rhce Variant Frequently Found in African Blacks by M.B. Hemker, P.C.

DAR, a New RhD Variant Involving Exons 4, 5, and 7, Often in Linkage With ceAR, a New Rhce Variant Frequently Found in African Blacks by M.B. Hemker, P.C.
Donor versus no-donor comparison of newly diagnosed myeloma patients included in the HOVON-50 multiple myeloma study by Henk M. Lokhorst, Bronno van der.

Donor versus no-donor comparison of newly diagnosed myeloma patients included in the HOVON-50 multiple myeloma study by Henk M. Lokhorst, Bronno van der.
by Robert A. Kyle, Morie A. Gertz, Philip R. Greipp, Thomas E

by Robert A. Kyle, Morie A. Gertz, Philip R. Greipp, Thomas E
by Robert F. Todd, Scott D. Gitlin, Linda J. Burns, and

by Robert F. Todd, Scott D. Gitlin, Linda J. Burns, and
F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis by Samantha C. Gouw, H. Marijke.

F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis by Samantha C. Gouw, H. Marijke.
Prophylactic human granulocyte colony-stimulating factor after induction therapy in pediatric acute myeloid leukemia by Thomas Lehrnbecher, Martin Zimmermann,

Prophylactic human granulocyte colony-stimulating factor after induction therapy in pediatric acute myeloid leukemia by Thomas Lehrnbecher, Martin Zimmermann,
Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis by Paolo Prandoni,

Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis by Paolo Prandoni,
by Toru Takahashi, Toshiaki Yujiri, and Yukio Tanizawa

by Toru Takahashi, Toshiaki Yujiri, and Yukio Tanizawa
Variations in glycosylation of von Willebrand factor with O-linked sialylated T antigen are associated with its plasma levels by Carina J. M. van Schooten,

Variations in glycosylation of von Willebrand factor with O-linked sialylated T antigen are associated with its plasma levels by Carina J. M. van Schooten,
Anti-CD20 monoclonal antibody treatment in 6 patients with therapy-refractory chronic graft-versus-host disease by Marijke R. Canninga-van Dijk, Hanneke.

Anti-CD20 monoclonal antibody treatment in 6 patients with therapy-refractory chronic graft-versus-host disease by Marijke R. Canninga-van Dijk, Hanneke.

Similar presentations

Ads by Google